Prioritizing Development of CPI-818 for T Cell Lymphomas, Autoimmune and Allergic Diseases
Plans to Begin Phase 2 Clinical Trial of Ciforadenant in Front Line Renal Cell Cancer (RCC) in Partnership with Kidney Cancer Consortium in Q3 2022
Read more at globenewswire.com